RNase L in health and disease - What did we learn recently?

Journal of Chronic Fatigue Syndrome

Volumn 11, Issue 2, 2003, Pages 97-109

  Englebienne, Patrick ^a,b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b R E D LABORATORIES   (Belgium)

Author keywords

2 ,5 oligoadenylate synthetase; Chronic fatigue syndrome; Double stranded RNA dependent protein kinase; RNase L; Type I interferon

Indexed keywords

2',5' OLIGOADENYLIC ACID; RIBONUCLEASE;

APOPTOSIS; BACTERIAL INFECTION; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CHLAMYDIASIS; CHRONIC FATIGUE SYNDROME; DEFENSE MECHANISM; DEREGULATION; ENZYME DEGRADATION; HUMAN; IMMUNOCOMPETENT CELL; POLYMERASE CHAIN REACTION; REVIEW; RNA REPLICATION; VIRUS INFECTION;

EID: 0042521083     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v11n02_07     Document Type: Review

References (49)

1. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18 (Suppl. 1):S96-S104.
2. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55:255-281.
3. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95:15623-15628.
4. Vojdani A, Choppa PC, Lapp CW. Down regulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic l'atigue immune dysfunction syndrome. J Clin Lab Immunol 1998; 50:1-16.
5. Grolleau A, Kaplan MJ, Hanash SM, Beretta L, Richardson B. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 2000; 106:1561-1568.
6. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun 1996; 9:661-666.
7. Bonnevie-Nielsen V, Martensen PM, Justesen J, et al. The antiviral 2′,5′-oligoadenylate synthetase is persistently activated in type 1 diabetes. Clin Immunol 2000; 96:11-18.
8. Flodstrom M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol. 2002; 3:373-382.
9. Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998; 78:55-113.
10. Natelson BH. A status report on chronic fatigue syndrome. Environ Health Perspect 2002; 110:673-677.
11. De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99-105.
12. Bastide L, Demettre E, Martinand-Mari C, Lebleu B. Interferon and the 2-5A/pathway. In: P. Englebienne & K. De Meirleir (Eds.), Chronic Fatigue Syndrome, A Biological Approach. 2002; (pp. 1-15). Boca Raton: CRC Press.
13. Hartmann R, Norby PL, Martensen PM, et al. Activation of 2′-5′ oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers. J Biol Chem 1998; 273:3236-3246.
14. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413:732-738.
15. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32:1958-1968.
16. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-760.
17. Magnusson, M, Magnusson S, Vallin H, Ronnblom L, Alm GV. Importance of CpG dinucleotides in activation of natural IFN-α-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 2001; 54:543-550.
18. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30:181-184.
19. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Genet 2002; 70:1299-1304.
20. Englebienne P, Verhas M, Herst CV, De Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypotheses 2002; in press.
21. Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation. J Biol Chem 1995; 270:4133-4137.
22. Dong B, Silverman RH. Alternative function of a protein kinase homology domain in 2′,5′-oligoadenylate dependent RNase L. Nucleic Acids Res 1999; 27:439-445.
23. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T. Cloning and characterization of a RNase L inhibitor. J Biol Chem 1995; 270:13308-13317.
24. Englebienne P, Herst CV, D'Haese A, et al. Ribonuclease L inhibitor: a member of the ATP-binding cassette super family. In: P. Englebienne & K. De Meirleir (Eds.), Chronic Fatigue Syndrome, A Biological Approach 2002 (pp. 73-97). Boca Raton: CRC Press.
25. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002; 415:88-92.
26. Castelli J, Wood KA, Youle RJ. The 2-5A system in viral infection and apoptosis. Biomed Pharmacother 1998; 52:386-390.
27. Bisbal C, Silhol M, Laubenthal H, et al. The 2′-5′ oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol 2000; 20:4959-4969.
28. Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T. The 2-5A/RNase L/RLI pathway regulates mitochondrial mRNAs stability in IFNα-treated H9 cells. J Biol Chem 2001; 276:48473-48482.
29. Rusch L, Zhou A, Silverman RH. Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-β. J Interferon Cytokine Res 2000; 20:1091-1100.
30. Li XL, Blackford JA, Judge CS, et al. RNase-L-dependent destabilization of interferon-induced mRNAs. J Biol Chem 2000; 275:8880-8888.
31. D'Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr, Borden EC. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 1996; 157:4100-4108.
32. Loeb KR, Haas AL. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 1992; 267:7806-7813.
33. Hamerman JA, Hayashi F, Schroeder LA, et al. Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog. J Immunol 2002; 168:2415-2423.
34. Li XL, Hassel BA. Involvement of proteasomes in gene induction by interferon and double-stranded RNA. Cytokine 2001; 14:247-252.
35. D'Cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 1996; 93:211-215.
36. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277:9976-9981.
37. Malakhova O, Malakhov M, Hetherington C, Zhang DE. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem 2002; 277:14703-14711.
38. Suhadolnik RJ, Peterson DL, O'Brien K. et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997; 17:377-385.
39. Shetzline SE, Suhadolnik RJ. Characterization of a 2′.5′-oligoadenylate (2-5A)-dependent 37-kDa RNase L: azido photoaffinity labeling and 2-5A-dependent activation. J Biol Chem 2001; 276:23707-23711.
40. Shetzline SE. Martinand-Mari C, Reichenbach NL, et al. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 2002; 22:443-456.
41. Demettre E, Bastide L, D'Haese A, et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002; 277:35746-35751.
42. Roelens S, Herst CV, D'Haese A, et al. G-actin cleavage parallels 2-5A-dependent RNase L cleavage in peripheral blood mononuclear cells. Relevance to a possible serum-based screening test for deregulations in the 2-5A pathway. J Chronic Fatigue Syndrome 2001; 8:63-82.
43. Marié I, Blanco J, Rebouillat D, Hovanessian AG. 69-kDa and 100-kDa isoforms of interferon-induced (2′-5′) oligoadenylate synthetase exhibit differential catalytic parameters. Eur J Biochem 1997; 248:558-566.
44. De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. Arch Intern Med 2000; 160:3270-3277.
45. Englebienne P, Herst CV, De Smet K, D'Haese A, De Meirleir K. Interactions between RNase L ankyrin-like domain and ABC transporters as a possible origin for pain, ion transport, CNS and immune disorders of chronic fatigue immune dysfunction syndrome. J Chronic Fatigue Syndrome 2001; 8:83-102.
46. Chaudhuri A, Watson WS, Pearn J, Behan PO. The symptoms of chronic fatigue syndrome are related to abnormal ion channel function. Med Hypotheses 2000; 54:59-63.
47. De Becker P, McGregor N, De Smet K, De Meirleir K. Current advances in CFS therapy. In: P. Englebienne & K. De Meirleir (Eds.). Chronic Fatigue Syndrome, A Biological Approach. 2002; (pp. 229-263). Boca Raton: CRC Press.
48. Ushijima H, Rytik PG, Schacke H, Scheffer U, Muller WE, Schroder HC. Mode of action of the anti-AIDS compound poly(I).poly(C12U (Ampligen): activator of 2′,5′-oligoadenylate synthetase and double-stranded RNA-dependent kinase. J Interferon Res 1993; 13:161-171.
49. Vojdani A, Ghoneum M, Choppa PC, Magtoto L, Lapp CW. Elevated apoptotic cell population in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA. J Intern Med 1997; 242:465-478.